Knight Therapeutics Inc. (TSX:GUD)

Knight Therapeutics Revenue

Knight Therapeutics had revenue of 144.21M CAD in the quarter ending June 30, 2026, with 34.33% growth. This brings the company's revenue in the last twelve months to 547.31M, up 42.32% year-over-year. In the year 2025, Knight Therapeutics had annual revenue of 450.09M with 21.22% growth.

• Revenue (ttm): 547.31M
• Revenue Growth: +42.32%
• P/S Ratio: 1.85
• Revenue / Employee: 659.40K
• Employees: 830
• Market Cap: 1.01B

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	450.09M	78.78M	21.22%
Dec 31, 2024	371.30M	43.11M	13.13%
Dec 31, 2023	328.20M	34.64M	11.80%
Dec 31, 2022	293.56M	50.09M	20.57%
Dec 31, 2021	243.48M	43.96M	22.03%
Dec 31, 2020	199.52M	152.06M	320.39%
Dec 31, 2019	47.46M	34.96M	279.69%
Dec 31, 2018	12.50M	3.87M	44.78%
Dec 31, 2017	8.63M	2.69M	45.35%
Dec 31, 2016	5.94M	4.90M	472.81%
Dec 31, 2015	1.04M	672.00K	184.11%
Dec 31, 2014	365.00K	-	-

Data Source: Fiscal.ai Last updated: Aug 6, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 2, 2026

Data Sources Report a data error